• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Acurx Pharmaceuticals Inc.

    3/17/25 4:37:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email
    S-8 1 tm258942d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 17, 2025

     

    Registration No. 333-   

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Acurx Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-3733567
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    259 Liberty Avenue

    Staten Island, NY 10305

    (Address, including zip code, of registrant’s principal executive offices)

     

    2021 Equity Incentive Plan

    (Full Title of the Plan)

     

    David P. Luci

    President and Chief Executive Officer

    Acurx Pharmaceuticals, Inc.

    259 Liberty Avenue

    Staten Island, NY 10305

    Telephone: (917) 533-1469

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies to:

    Ivan K. Blumenthal, Esq.

    Jeffrey D. Cohan, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    919 Third Avenue New York, NY 10022

    (212) 935-3000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
           
    Non-accelerated filer x Smaller reporting company x
           
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement registers an aggregate of 681,227 additional shares of common stock, par value $0.001 per share (“common stock”), of Acurx Pharmaceuticals, Inc. (the “Registrant”) reserved under the 2021 Equity Incentive Plan (the “Plan”), representing an increase of 681,227 shares reserved under the Plan effective January 2, 2025 by operation of the 2021 Plan’s “evergreen” provision. This registration statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (File Nos. 333-258026, 333-263609, 333-270585 and 333-277994) relating to an employee benefit plan are effective. The information contained in the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission on July 19, 2021 (File No. 333-258026) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

     

     2 

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Filed
    Herewith
      Incorporated
    by
    Reference
    herein from
    Form or
    Schedule
      Filing
    Date
      SEC File/
    Reg.
    Number
                         
    4.1   Form of Common Stock Certificate.       Form S-1
    (Exhibit 4.1)
      May 27, 2021   333-256516
                         
    5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.   X            
                         
    23.1   Consent of CohnReznick LLP, independent registered public accounting firm.   X            
                         
    23.2   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)   X            
                         
    24.1   Power of Attorney (included on the signature page hereof)   X            
                         
    107   Filing Fee Table   X            

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on March 17, 2025.

     

      ACURX PHARMACEUTICALS, INC.
         
      By: /s/ David P. Luci
        David P. Luci
        Chief Executive Officer and President

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints each of David P. Luci and Robert G. Shawah, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ David P. Luci   President, Chief Executive Officer and Director
    (Principal Executive Officer)
      March 17, 2025
    David P. Luci
             
    /s/ Robert G. Shawah   Chief Financial Officer (Principal Financial and Accounting Officer)   March 17, 2025
    Robert G. Shawah
             
    /s/ Robert J. DeLuccia   Executive Chairman   March 17, 2025
    Robert J. DeLuccia
             
    /s/ Carl V. Sailer   Director   March 17, 2025
    Carl V. Sailer
             
    /s/ Jack H. Dean   Director   March 17, 2025
    Jack H. Dean
             
    /s/ Joseph C. Scodari   Director   March 17, 2025
    Joseph C. Scodari
             
    /s/ Thomas Harrison   Director   March 17, 2025
    Thomas Harrison
             
    /s/ James Donohue   Director   March 17, 2025
    James Donohue

     

     

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    SEC Filings

    View All

    SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.

    424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/11/26 4:21:38 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

    S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/2/26 4:48:05 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.

    EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    1/7/26 12:15:11 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

    STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, further strengthens Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx h

    2/2/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

    The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the modes of DNA polymerase pol IIIC (PolC) action and resistance are conserved across important species of Gram-positive multidrug resistant organismsThe previous LUMC-Acurx Health~Holland project successfully elucidated the structure of PolC from E. faecium, a critical Gram-positive human pathogen, in complex with two Acurx pol IIIC inhibitors. These data, using both Acrux's Phase 3-ready ibezapolstat for treatment of C. difficile infection and an advanced preclinical pol IIIC inhibitor from the ong

    11/18/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.   Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: On August 4, 2025, we effected a 1-for-20 reverse stock split of our issued and outstanding shares of common stock, and as a result of the reverse-stock-split, on August 26, 2025, we regained compliance with the minimum bid price requirement of

    11/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:47:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Luci David P

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:46:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Deluccia Robert J

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:45:47 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    11/29/21 8:33:36 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/24 2:39:21 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:59:03 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:52:45 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.   Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: On August 4, 2025, we effected a 1-for-20 reverse stock split of our issued and outstanding shares of common stock, and as a result of the reverse-stock-split, on August 26, 2025, we regained compliance with the minimum bid price requirement of

    11/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date:                           Wednesday, November 12, 2025 Time:                       

    10/27/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2025.   Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, we announced that the Indian Patent Office granted a new patent for our DNA polymerase IIIC inhibitors which expires in December 2039, subject to extension. This constitutes another significant building block for our ongoing preclinical antib

    8/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care